TWI603965B - 苯并哌喃衍生物或其鹽類用以製造基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑之用途 - Google Patents

苯并哌喃衍生物或其鹽類用以製造基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑之用途 Download PDF

Info

Publication number
TWI603965B
TWI603965B TW103124716A TW103124716A TWI603965B TW I603965 B TWI603965 B TW I603965B TW 103124716 A TW103124716 A TW 103124716A TW 103124716 A TW103124716 A TW 103124716A TW I603965 B TWI603965 B TW I603965B
Authority
TW
Taiwan
Prior art keywords
phenoxy
amino
oxo
methylsulfonyl
pain
Prior art date
Application number
TW103124716A
Other languages
English (en)
Chinese (zh)
Other versions
TW201536764A (zh
Inventor
田中啓一
森本貴美子
Original Assignee
富山化學工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富山化學工業股份有限公司 filed Critical 富山化學工業股份有限公司
Publication of TW201536764A publication Critical patent/TW201536764A/zh
Application granted granted Critical
Publication of TWI603965B publication Critical patent/TWI603965B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
TW103124716A 2013-07-18 2014-07-18 苯并哌喃衍生物或其鹽類用以製造基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑之用途 TWI603965B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18

Publications (2)

Publication Number Publication Date
TW201536764A TW201536764A (zh) 2015-10-01
TWI603965B true TWI603965B (zh) 2017-11-01

Family

ID=52346269

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103124716A TWI603965B (zh) 2013-07-18 2014-07-18 苯并哌喃衍生物或其鹽類用以製造基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑之用途

Country Status (22)

Country Link
US (3) US20150353519A1 (enExample)
EP (2) EP3078372B1 (enExample)
JP (2) JP5802868B2 (enExample)
CN (1) CN105407887B (enExample)
AU (1) AU2014291149B2 (enExample)
CA (1) CA2918325C (enExample)
CY (2) CY1118140T1 (enExample)
DK (2) DK3078372T3 (enExample)
ES (2) ES2642440T3 (enExample)
HR (2) HRP20161317T1 (enExample)
HU (2) HUE034661T2 (enExample)
IL (1) IL243550B (enExample)
LT (2) LT2929880T (enExample)
NO (1) NO3078372T3 (enExample)
PL (2) PL2929880T3 (enExample)
PT (2) PT2929880T (enExample)
RS (2) RS55394B1 (enExample)
RU (2) RU2750540C2 (enExample)
SI (2) SI2929880T1 (enExample)
SM (3) SMT201700080T1 (enExample)
TW (1) TWI603965B (enExample)
WO (1) WO2015008827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (zh) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108670A2 (en) * 2005-04-15 2006-10-19 Novartis Ag Use of cd25 antibodies in immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
WO1997023714A1 (de) * 1995-12-21 1997-07-03 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
BR112014002407A2 (pt) 2011-08-30 2017-02-21 Toyama Chemical Co Ltd método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108670A2 (en) * 2005-04-15 2006-10-19 Novartis Ag Use of cd25 antibodies in immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K TANAKA,et al."Pharmacological Studies on 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-on e(T-614 )a ,Novel Antiinflammatory Agent. 3rd Communication:The Involvement of Bradykinin in Its Analgesic Actions",J.Pharmacobio-Dyn.,15, 641-647 ,1992. *
RE. Jones,et al."Myelin basic protein-specific T lymphocytes induce chronic relapsing experimental autoimmune encephalomyelitis in lymphocyte-deficient SCID/ mice",Journal of Neuroimmunology, 93, 1999, 92~101. *
Y Aikawa,et al."A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis",Journal of Neuroimmunology, 89, 1998,35–42. *
YL Kama,et al."Synthesis and bradykinin inhibitory activity of novel non-peptide compounds, and evaluation of in vivo analgesic activity",Bioorganic & Medicinal Chemistry, 18,2010,2327–2336. *

Also Published As

Publication number Publication date
CA2918325C (en) 2018-06-26
RS55394B1 (sr) 2017-04-28
SMT201700080B (it) 2017-03-08
WO2015008827A1 (ja) 2015-01-22
SMT201700080T1 (it) 2017-03-08
EP3078372B1 (en) 2017-09-13
PL3078372T3 (pl) 2018-02-28
LT2929880T (lt) 2016-11-25
SI2929880T1 (sl) 2016-12-30
US9918963B2 (en) 2018-03-20
CY1118140T1 (el) 2017-06-28
AU2014291149A1 (en) 2016-02-11
EP2929880A1 (en) 2015-10-14
RU2750540C2 (ru) 2021-06-29
EP2929880A4 (en) 2015-10-14
US20160228404A1 (en) 2016-08-11
ES2642440T3 (es) 2017-11-16
AU2014291149B2 (en) 2017-05-04
DK3078372T3 (en) 2017-10-16
DK2929880T3 (da) 2017-01-02
HRP20161317T1 (hr) 2016-12-16
HUE029800T2 (en) 2017-04-28
TW201536764A (zh) 2015-10-01
JP5802868B2 (ja) 2015-11-04
PT2929880T (pt) 2016-11-08
HUE034661T2 (en) 2018-02-28
EP2929880B1 (en) 2016-09-14
US20150353519A1 (en) 2015-12-10
EP3078372A1 (en) 2016-10-12
PT3078372T (pt) 2017-10-18
IL243550B (en) 2019-06-30
CN105407887A (zh) 2016-03-16
CA2918325A1 (en) 2015-01-22
HK1222556A1 (zh) 2017-07-07
JP6060231B2 (ja) 2017-01-11
CN105407887B (zh) 2018-09-04
SI3078372T1 (en) 2018-01-31
US20160228406A1 (en) 2016-08-11
ES2593527T3 (es) 2016-12-09
RU2641301C2 (ru) 2018-01-17
SMT201700606T1 (it) 2018-01-11
NO3078372T3 (enExample) 2018-02-10
RU2017131951A (ru) 2019-02-06
HRP20171497T1 (hr) 2017-11-17
IL243550A0 (en) 2016-02-29
LT3078372T (lt) 2017-11-27
RU2017131951A3 (enExample) 2020-12-18
RU2016105141A (ru) 2017-08-23
CY1119496T1 (el) 2018-03-07
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
RS56489B1 (sr) 2018-01-31
JPWO2015008827A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
JP6589251B2 (ja) グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
US20230094124A1 (en) Morphic forms of danicopan
CA2960876C (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
JP7804370B2 (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
TW201536764A (zh) 基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑
CN101282724A (zh) 具有药学活性的四氢-吡咯并[1,2-b]异噻唑1,1-二氧化物
HK1222556B (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor